Document is current
Any future updates will be listed below
-
Authors
Smith, Tyler K. T.
Townsend, Logan K. https://orcid.org/0000-0002-4311-2702
Smiles, William J. https://orcid.org/0000-0002-6846-689X
Oakhill, Jonathan S. https://orcid.org/0000-0002-9475-1440
Fullerton, Morgan D. https://orcid.org/0000-0002-7221-306X
Steinberg, Gregory R. https://orcid.org/0000-0001-5425-8275
- License Information
-
More Information
Article History
Received: 14 December 2024
Accepted: 5 December 2025
First Online: 12 January 2026
Competing interests
: G.R.S. is a cofounder and shareholder of Espervita Therapeutics, a company developing new medications for liver and kidney fibrosis and liver cancer. McMaster University has received funding from Cambrian Biosciences, Catalym, Espervita Therapeutics, Esperion Therapeutics, Merck, Nestle, Novo Nordisk and Poxel Pharmaceuticals for research conducted in the laboratory of G.R.S. G.R.S. has received consulting/speaking fees from Astra Zeneca, Curie.Bio, Eli Lilly, Esperion Therapeutics, Korro Bio, Keros Therapeutics, Merck, Poxel Pharmaceuticals and Versant Ventures. The University of Ottawa has received funding from Allysta Pharmaceuticals for research conducted in the laboratory of M.D.F. T.K.T.S., L.K.T., W.J.S. and J.S.O. declare no competing interests.
